| Rank |
Status |
Study |
| 1 |
Unknown †
|
Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder
| Condition: |
Depression |
| Interventions: |
Other: active rTMS and active Venlafaxine; Other: active rTMS and sham Venlafaxine; Other: sham rTMS and active Venlafaxine |
| Outcome Measures: |
The primary outcome measure is remission; fMRI; CGI; QIDS-C30; UKU Scale |
|
| 2 |
Recruiting
|
Venlafaxine PK Following Bariatric Surgery
| Conditions: |
Roux en Y Gastric Bypass; Sleeve Gastrectomy |
| Intervention: |
Drug: Venlafaxine IR and Venlafaxine XR |
| Outcome Measures: |
Venlafaxine Plasma Concentrations/Area-Under-the-Curve (AUC); Secondary PK Characteristics (Composite) |
|
| 3 |
Recruiting
|
Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
| Conditions: |
Bariatric Surgery; Gastric Bypass; Roux-en-Y Gastric Bypass |
| Intervention: |
Drug: venlafaxine ER (extended-release) 75 mg |
| Outcome Measure: |
Venlafaxine levels pre- and post-gastric bypass |
|
| 4 |
Recruiting
|
ADAPT: Addressing Depression and Pain Together
| Conditions: |
Depression; Back Pain |
| Interventions: |
Other: Combination Treatment with Higher-dose venlafaxine + PST-DP; Drug: Higher-dose venlafaxine and supportive management |
| Outcome Measures: |
Depression: Patient Health Questionnaire-9; Pain: 20-Point Numeric Rating Scale; Self-Efficacy: Chronic Pain Self-Efficacy Scale |
|
| 5 |
Recruiting
|
Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer
| Condition: |
Hot Flashes in Men With Prostate Cancer Receiving Androgen Ablation Therapy |
| Interventions: |
Drug: Gabapentin; Drug: Venlafaxine |
| Outcome Measures: |
Changes in quality of life; compare toxicity rates between the gabapentin and venlafaxine treatment groups; Assess changes in the hot flash scores for the two arms; Assess changes in quality of life using the Hot flash related Daily Interference Scale (HFRDIS) |
|
| 6 |
Recruiting
|
Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
| Condition: |
Major Depression |
| Intervention: |
Drug: venlafaxine,fluoxetine |
| Outcome Measures: |
change of 24-item Hamilton Rating Scale for Depression total score; the mean change of HAMD-24 subscale score in items 10, 11, 12, 13 (anxiety and somatizations) at endpoint |
|
| 7 |
Recruiting
|
Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
| Condition: |
Major Depressive Disorder |
| Interventions: |
Drug: ketamine venlafaxine; Drug: Venlafaxine |
| Outcome Measure: |
Depressive state |
|
| 8 |
Recruiting
|
The HELP PAIN Trial
| Condition: |
Neck Pain |
| Intervention: |
Drug: Venlafaxine |
| Outcome Measures: |
Average neck pain; Chronic neck pain |
|
| 9 |
Recruiting
|
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
| Conditions: |
Alzheimer's Disease; Depression |
| Interventions: |
Drug: Placebo; Drug: Venlafaxine |
| Outcome Measures: |
225 mg daily dose of venlafaxine over 12 weeks will produce changes in response on the modified AD Cooperative Study-Clinical Global Impression of Change and the Cornell Scale for Depression in Dementia.; Examine in a proof of concept, 12-week randomized controlled trial, the safety of venlafaxine at a target dose of 225 mg daily for the treatment of Depression in patients with AD. |
|
| 10 |
Not yet recruiting
|
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
| Conditions: |
Major Depressive Disorder; Major Depressive Episode |
| Intervention: |
Drug: Venlafaxine extended release |
| Outcome Measure: |
Change from baseline in depressive symptoms on the Hamilton Depression Rating Scale-17 items |
|
| 11 |
Recruiting
|
Venlafaxine Augmentation in Treatment Resistant Depression
| Condition: |
Depression |
| Interventions: |
Drug: Venlafaxine; Drug: Quetiapine |
| Outcome Measures: |
Hamilton Depression Rating Scale (HDRS); Self reported psychopathology (Beck Depression Inventory [BDI], State-Trait Anxiety Inventory [STAI]); Cognitive function |
|
| 12 |
Unknown †
|
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
| Condition: |
Depressive Disorder, Major |
| Interventions: |
Drug: Mirtazapine; Drug: Venlafaxine |
| Outcome Measures: |
Categorial response to the medication. Categorial response is defined on the basis of CGI Improvement scale and 50% reduction in MADR-S score; Tolerability of treatment as assessed using the DOTES scale; Cognitive deficits as judged by the SKT system; Self assessment of depression and anxiety using Beck's Depression/Anxiety Inventory (BDI/BAI); Changes is blood levels of homocysteine, folate, vit B12, P11 |
|
| 13 |
Unknown †
|
Pharmacogenomics Studies of Antidepressants
| Conditions: |
Major Depressive Disorder; Antidepressive Agents; Pharmacogenetics; Venlafaxine; Fluoxetine |
| Interventions: |
Drug: Venlafaxine; Drug: Fluoxetine |
| Outcome Measures: |
Hamilton Depression Rating Scale (HDRS); C-reactive Protein and IL-6; fasting blood glucose, lipid profiles |
|
| 14 |
Recruiting
|
International Study to Predict Optimised Treatment - in Depression
| Condition: |
Major Depressive Disorder |
| Interventions: |
Drug: Escitalopram; Drug: Sertraline; Drug: Venlafaxine XR |
| Outcome Measures: |
To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDD; To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months. |
|
| 15 |
Recruiting
|
A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder
| Condition: |
Major Depressive Disorder |
| Interventions: |
Drug: Sustained-Release Desvenlafaxine Hydrochloride; Drug: Sustained-Release Venlafaxine Hydrochloride |
| Outcome Measures: |
Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17); Change From Baseline on the Clinical Global Impression Scale; Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Scale; Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 10; Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS); Change From Baseline on the Visual Analogue Scale-Pain Intensity (VAS-PI); Number of Participants in Remission Based on the HAM-D17 at Week 10 |
|
| 16 |
Unknown †
|
Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury
| Condition: |
Spinal Cord Injury |
| Interventions: |
Drug: Venlafaxine HCI; Other: Placebo |
| Outcome Measures: |
The Patient Health Questionnaire-9 (PHQ-9); The Beck Scale for Suicide Ideation (BSS); 16 item Quick Inventory of Depressive Symptomatology (QIDS- SR16); The SCI Pain Instrument (SCIPI); The Adherence and Side Effects Checklist; CAGE & Drug Use; Generalized Anxiety Disorder-7 (GAD-7); The Perceived Stress Scale (PSS); Life Experiences Survey - Disability (LES-D); The Received Social Support and Social Undermining Scale (RSS/SU); Measure of the Quality of the Environment; The Perceived Handicap Questionnaire (PHQ); Craig Handicap Assessment and Reporting Form - Short Form (CHART-SF); The SF-12 Health Status Questionnaire - 12 |
|
| 17 |
Unknown †
|
Electroencephalography (EEG) Signal Processing
| Condition: |
Major Depressive Disorder |
| Interventions: |
Drug: Venlafaxine; Drug: bupropion; Drug: escitalopram; Other: Psychotherapy; Drug: Duloxetine |
| Outcome Measure: |
Machine learning |
|
| 18 |
Recruiting
|
Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Depression
| Condition: |
Depression |
| Interventions: |
Procedure: repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: counseling |
| Outcome Measures: |
Time for relapse; Hamilton Depression Rating Scale; Illness severity change; subject functioning |
|
| 19 |
Recruiting
|
Prolonging Remission in Depressed Elderly (PRIDE)
| Condition: |
Depression |
| Interventions: |
Drug: lithium and Venlafaxine; Procedure: ECT |
| Outcome Measures: |
Long-term antidepressant efficacy (Hamilton Rating Scale for Depression); Level of functioning (SF-36); Tolerability (Mini Mental State Examination [MMSE]); Tolerability (California Verbal Learning Test [CVLT-II], Autobiographical Memory Interview-Short Form [AMI-SF]); Tolerability (Trail Making Tests, DRS-IP and Delis-Kaplan Executive Function System, Verbal Fluency; Safety (Udvalg for Kliniske Undersogelser [UKU] Side Effects Rating Scale) |
|
| 20 |
Recruiting
|
Predict Antidepressant Responsiveness Using Pharmacogenomics
| Conditions: |
Depression; Depressive Symptoms |
| Interventions: |
Drug: SSRI class antidepressant; Drug: non-SSRI class antidepressant |
| Outcome Measure: |
Presences of each individual symptom of depression at 1,2,4,6,12 weeks |
|
